The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19

Saburi, Ehsan; Abazari, Mohammad Foad; Hassannia, Hadi; Mansour, Reyhaneh Nassiri; Eshaghi-Gorji, Reza; Gheibi, Mobina; Rahmati, Mohammad; Enderami, Seyed Ehsan

doi:10.1016/j.gene.2021.145471

Cited by 15 publications

(13 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many clinical trials in different conditions associated with these cells are currently performed for the disease [ 24 ]. MSCs have two main effects, namely immunomodulation [ 25 ] and differentiation [ 26 ]. Meanwhile, Wharton’s jelly-derived MSCs are easily and non-invasively isolated from neonatal tissues [ 27 ] and show a higher pluripotential property compared to other sources of MSCs [ 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

et al. 2021

View full text Add to dashboard Cite

Background Mesenchymal stem cells (MSCs) have received particular attention because of their ability to modulate the immune system and inhibit inflammation caused by cytokine storms due to SARS-CoV-2. New alternative therapies may reduce mortality rates in patients with COVID19. This study aimed to assess the safety and efficacy of injecting intravenous Wharton’s jelly-derived MSCs in patients with COVID-19 as a treatment. Methods In this study, five patients with severe COVID-19 were treated with Wharton’s jelly-derived mesenchymal stem cells (150 × 106 cells per injection). These patients were subject to three intravenous injections 3 days apart, and monitoring was done on days 0, 3, 6, and 14 in routine tests, inflammatory cytokines, and flow cytometry of CD4 and CD8 markers. A lung CT scan was performed on base and days 14 and 28. In addition, IgM and IgG antibodies against SARS-CoV-2 were measured before and after treatment. Results The results showed that IL-10 and SDF-1 increased after cell therapy, but VEGF, TGF-β, IFN-γ, IL-6, and TNFα decreased. Routine hematology tests, myocardial enzyme tests, biochemical tests, and inflammation tests were performed for all patients before and after cell therapy on base and days 3, 6, and 14, which indicated the improvement of test results over time. COVID-19 antibody tests rose in 14 days after WJ-MSC injection. The total score of zonal involvement in both lungs was improved. Conclusions In patients, the trend of tests was generally improving, and we experienced a reduction in inflammation. No serious complications were observed in patients except the headache in one of them, which was resolved without medication. In this study, we found that patients with severe COVID-19 in the inflammatory phase respond better to cell therapy. More extensive clinical trials should be performed in this regard. Trial registration IRCT, IRCT20190717044241N2. Registered April 22, 2020.

show abstract

Section: Introductionmentioning

confidence: 99%

Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

et al. 2021

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 induces its pathological changes via exacerbating cytokine production, which leads to many complications that may become severe in some cases. Stem cells have specific cytokines that tightly derive immunomodulation (Figure ), which may not only be helpful in controlling the SARS-CoV-2 infection severity ,− but also extend beyond patient recovery specifically from severe infection …”

Section: Next Generation Of Antimicrobials: Carbon-based Nanomaterialsmentioning

confidence: 99%

“…Stem cells have specific cytokines 126 that tightly derive immunomodulation (Figure 1), which may not only be helpful in controlling the SARS-CoV-2 infection severity 125,127−129 but also extend beyond patient recovery specifically from severe infection. 130…”

Section: Next Generation Of Antimicrobialsmentioning

confidence: 99%

Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era

et al. 2021

View full text Add to dashboard Cite

Therapeutic options for the highly pathogenic human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the current pandemic coronavirus disease (COVID-19) are urgently needed. COVID-19 is associated with viral pneumonia and acute respiratory distress syndrome causing significant morbidity and mortality. The proposed treatments for COVID-19 have shown little or no effect in the clinic so far. Additionally, bacterial and fungal pathogens contribute to the SARS-CoV-2-mediated pneumonia disease complex. The antibiotic resistance in pneumonia treatment is increasing at an alarming rate. Therefore, carbon-based nanomaterials (CBNs), such as fullerene, carbon dots, graphene, and their derivatives constitute a promising alternative due to their wide-spectrum antimicrobial activity, biocompatibility, biodegradability, and capacity to induce tissue regeneration. Furthermore, the antimicrobial mode of action is mainly physical ( e.g. , membrane distortion), characterized by a low risk of antimicrobial resistance. In this Review, we evaluated the literature on the antiviral activity and broad-spectrum antimicrobial properties of CBNs. CBNs had antiviral activity against 13 enveloped positive-sense single-stranded RNA viruses, including SARS-CoV-2. CBNs with low or no toxicity to humans are promising therapeutics against the COVID-19 pneumonia complex with other viruses, bacteria, and fungi, including those that are multidrug-resistant.

show abstract

“…Herein we used a unique micro-nanopatterning technique to enable exploration of the relationship between the critical adhesion area of individual cells and the number of integrin-ligand bindings. Mesenchymal stem cells (MSCs) are an important cell type with rich cell behaviors following cell adhesion on biomaterials [65][66][67][68][69][70]; in the present study, human MSCs (hMSCs) were employed as the model cells to examine cell adhesion on patterned surfaces.…”

Section: Introductionmentioning

confidence: 99%

Critical adhesion areas of cells on micro-nanopatterns

Zheng

Liu

et al. 2021

Nano Res.

View full text Add to dashboard Cite

Cell adhesion to extracellular matrices (ECM) is critical to physiological and pathological processes as well as biomedical and biotechnological applications. It has been known that a cell can adhere on an adhesive microisland only over a critical size. But no publication has concerned critical adhesion areas of cells on microislands with nanoarray decoration. Herein, we fabricated a series of micro-nanopatterns with different microisland sizes and arginine-glycine-aspartate (RGD) nanospacings on a nonfouling poly(ethylene glycol) background. Besides reproducing that nanospacing of RGD, a ligand of its receptor integrin (a membrane protein), significantly influences specific cell adhesion on bioactive nanoarrays, we confirmed that the concept of critical adhesion area originally suggested in studies of cells on micropatterns was justified also on the micro-nanopatterns, yet the latter exhibited more characteristic behaviors of cell adhesion. We found increased critical adhesion areas of human mesenchymal stem cells (hMSCs) on nanoarrayed microislands with increased RGD nanospacings. However, the numbers of nanodots with respect to the critical adhesion areas were not a constant. A unified interpretation was then put forward after combining nonspecific background adhesion and specific cell adhesion. We further carried out the asymptotic analysis of a series of micro-nanopatterned surfaces to obtain the effective RGD nanospacing on unpatterned free surfaces with densely grafted RGD, which could be estimated nonzero but has never been revealed previously without the assistance of the micro-nanopatterning techniques and the corresponding analysis.

show abstract

The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19

Cited by 15 publications

References 48 publications

Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era

Critical adhesion areas of cells on micro-nanopatterns

Contact Info

Product

Resources

About